Read by QxMD icon Read

Gynecologic cancer

Kemal Güngördük, İsa Aykut Özdemir, Özgü Güngördük, Varol Gülseren, Mehmet Gokçü, Muzaffer Sancı
BACKGROUND: Paralytic ileus developing after elective surgery is a common and uncomfortable complication and is considered inevitable after an intraperitoneal operation. OBJECTIVE: To investigate whether coffee consumption accelerates the recovery of bowel function after complete staging surgery of gynecological cancers. STUDY DESIGN: In this randomized controlled trial, 114 patients were preoperatively allocated to either postoperative coffee consumption with three times daily (n=58) or routine postoperative care without coffee consumption (n=56)...
October 22, 2016: American Journal of Obstetrics and Gynecology
(no author information available yet)
No abstract text is available yet for this article.
October 2016: International Journal of Gynecological Cancer
Jun Ye, Wei Chen, Zhi-Yong Wu, Jin-Hui Zhang, He Fei, Li-Wen Zhang, Ya-Hui Wang, Ya-Ping Chen, Xiao-Mei Yang
Epithelial ovarian cancer (EOC) is the major cause of deaths from gynecologic malignancies, and metastasis is the main cause of cancer related death. Collagen triple helix repeat containing-1 (CTHRC1) is a secreted protein that has the ability to inhibit collagen matrix synthesis. In this study, we found that high CTHRC1 expression was associated with poor prognosis of EOC. In vitro experiments showed that CTHRC1 promoted migration and invasion of ovarian cancer cells. CTHRC1 had no effect on ovarian cancer cells viability...
October 24, 2016: Oncology Reports
David Gaffney, Bill Small, Henry Kitchener, Sang Young Ryu, Akila Viswanathan, Ted Trimble, Al Covens, Sarikapan Wilailak, Arb-Aroon Lertkhachonsuk, Chomporn Sitathanee, Umesh Mahantshetty, Brandon Fisher, Susan Springer, Thomas Pollatz, Antonius Spiller, Monica Bacon, Anuja Jhingran
Eighty-seven percent of cervix cancer occurs in less-developed regions of the world, and there is up to an 18-fold difference in mortality rate for cervix cancer depending on the region of the world. The Cervix Cancer Research Network (CCRN) was founded through the Gynecologic Cancer InterGroup with the aim of improving access to clinical trials in cervix cancer worldwide, and in so doing improving standards of care. The CCRN recently held its first international educational symposium in Bangkok. Sixty-two participants attended from 16 different countries including Pakistan, India, Bangladesh, Thailand, Malaysia, Singapore, Philippines, Taiwan, China, Vietnam, Korea, Japan, Columbia, Brazil, Canada, and the United States...
November 2016: International Journal of Gynecological Cancer
Chunhao Niu, Xiaoying Sun, Weijing Zhang, Han Li, Liqun Xu, Jun Li, Benke Xu, Yanna Zhang
BACKGROUND: There is an abnormal expression of nuclear receptor subfamily 2 group F member 6 (NR2F6) in human cancers such as breast cancer, colon cancer, and acute myelogenous leukemia. However, its clinical significance in cervical cancer has not been established. We explored NR2F6 expression and its clinicopathological significance in early-stage cervical cancer. METHODS: NR2F6 expression in cervical cancer cell lines and cervical cancer tissues was determined by Western blotting, real-time PCR, and immunochemistry (IHC)...
October 20, 2016: International Journal of Molecular Sciences
Sarikapan Wilailak, Nuttapong Lertchaipattanakul
Between the years of 2010-2012, it was estimated there were a total of 112,392 new cases of cancers in Thailand, thus, the total age-standardized rate (ASR) per 100,000 is 137.6. In regards to the most prevalent types of cancer in female, breast cancer has the highest ASR, followed by cervical cancer (ASR=14.4); liver and bile duct cancer; colon and rectum cancer; trachea, bronchus and lung cancer; ovarian cancer (ASR=6.0); thyroid cancer; non-Hodgkin lymphoma and uterine cancer (ASR=4.3). The trend of cervical cancer in Thailand is decreasing, one key factor in making this possible was the employment of dual tract strategy (Pap smear and visual inspection with acetic acid [VIA]) by the government in 2005...
November 2016: Journal of Gynecologic Oncology
Ha Kyun Chang, Byoung Gie Kim, Ting Yan Shi, Rongyu Zang
No abstract text is available yet for this article.
November 2016: Journal of Gynecologic Oncology
Dong Hoon Suh, Miseon Kim, Hak Jae Kim, Kyung Hun Lee, Jae Weon Kim
In 2015, fourteen topics were selected as major research advances in gynecologic oncology. For ovarian cancer, high-level evidence for annual screening with multimodal strategy which could reduce ovarian cancer deaths was reported. The best preventive strategies with current status of evidence level were also summarized. Final report of chemotherapy or upfront surgery (CHORUS) trial of neoadjuvant chemotherapy in advanced stage ovarian cancer and individualized therapy based on gene characteristics followed...
November 2016: Journal of Gynecologic Oncology
John K Chan, James J Java, Katherine Fuh, Bradley J Monk, Daniel S Kapp, Thomas Herzog, Jeffrey Bell, Robert Young
OBJECTIVES: To determine the association between timing of adjuvant therapy initiation and survival of early stage ovarian cancer patients. METHODS: Data were obtained from women who underwent primary surgical staging followed by adjuvant therapy from two Gynecologic Oncology Group trials (protocols # 95 and 157). Kaplan-Meier estimates and Cox proportional hazards model adjusted for covariates were used for analyses. RESULTS: Of 497 stage I-II epithelial ovarian cancer patients, the median time between surgery and initiation of adjuvant therapy was 23days (25th-75th%: 12-33days)...
October 19, 2016: Gynecologic Oncology
Jennifer S Woo, Sophia K Apple, Peggy S Sullivan, Jian-Yu Rao, Nora Ostrzega, Neda A Moatamed
BACKGROUND: HER2/neu overexpression and/or amplification has been widely studied in a number of solid tumors, primarily in the breast. In gynecologic neoplasms, determination of HER2/neu status has not been well studied as a predictive biomarker in anti-HER2/neu treatment. METHODS: We systematically evaluated the HER2/neu reactions by immunohistochemistry and fluorescent in situ hybridization in malignant gynecologic neoplasms as experienced in our institution. RESULTS: The HER2/neu overexpression or amplification occurred in 8 % of the cancers of the gynecological organs in our series...
October 22, 2016: Diagnostic Pathology
Omar Mahmoud, Lara Hathout, Sherif G Shaaban, Mohamed A Elshaikh, Sushil Beriwal, William Small
PURPOSE: The Gynecologic Oncology group (GOG) 0263 trial is currently exploring whether adding chemotherapy to adjuvant radiotherapy improves recurrence-free and/or overall survival in stage IB-IIA cervical cancer patients with pathologic intermediate-risk factors. Using the National Cancer Data Base, we evaluated the benefit of adjuvant chemoradiotherapy over adjuvant radiotherapy alone in the community practice setting. MATERIALS: The analysis included 869 stage IB-IIA cervical cancer patients who underwent radical hysterectomy retrieving intermediate-risk factors justifying adjuvant therapy...
October 18, 2016: Gynecologic Oncology
Alison Cieslak, Gary Elkins, Tanima Banerjee, Jessica Marsack, Kimberly Hickman, Alisa Johnson, Norah Henry, Debra Barton
PURPOSE/OBJECTIVES: To determine the content, feasibility, and best outcome of a mind-body intervention involving self-directed hypnotic relaxation to target body image.
. DESIGN: A five-week, uncontrolled, unblinded feasibility intervention study.
. SETTING: Behavioral therapy offices in Ann Arbor, Michigan, and Waco, Texas.
. SAMPLE: 10 female breast cancer survivors and 1 breast and gynecologic cancer survivor...
November 1, 2016: Oncology Nursing Forum
H G Schnürch, S Ackermann, C D Alt, J Barinoff, C Böing, C Dannecker, F Gieseking, A Günthert, P Hantschmann, L C Horn, R Kürzl, P Mallmann, S Marnitz, G Mehlhorn, C C Hack, M C Koch, U Torsten, W Weikel, L Wölber, M Hampl
Purpose: This is an official guideline, published and coordinated by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO, Study Group for Gynecologic Oncology) of the Deutsche Krebsgesellschaft (DKG, German Cancer Society) and the Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG, German Society for Gynecology and Obstetrics). The number of cases with vulvar cancer is on the rise, but because of the former rarity of this condition and the resulting lack of literature with a high level of evidence, in many areas knowledge of the optimal clinical management still lags behind what would be required...
October 2016: Geburtshilfe und Frauenheilkunde
E Fehri, E Ennaifer, R Bel Haj Rhouma, L Guizani-Tabbane, I Guizani, S Boubaker
Toll-like receptor 9 (TLR9) plays a major role in the fight against DNA viruses infections. Despite its antitumor properties, inappropriate activation of TLR9 during chronic inflammation may cause the activation of transcription factors inducing pro-cancerous activities. Thus, the relationship between TLR9 and cancer remains highly confrontational especially in gynecological cancers and cervical cancer induced by viruses. In this review, we focus on the beneficial and detrimental role of TLR9 in gynecological carcinogenesis...
July 2016: Current Research in Translational Medicine
Y Liu, X Tan, Z Wang, Y Li, M Gao, Y Li, Z Fang, Y Sun, L Zhang, X Wang, Z Wei
OBJECTIVE: Adenomyosis is a common benign gynecological disease which has some malignant behaviors. Programmed cell death 4 (PDCD4) is a newly identified tumor suppressor gene which lowly expresses in various cancers. However, the expression status of PDCD4 in endometrium of adenomyosis patients has not been investigated. The aim of this study is to assess the expression levels of PDCD4 in endometrium of normal controls and adenomyosis patients. METHODS: The expression of PDCD4 in endometrium of normal controls and eutopic or ectopic endometrium of patients with adenomyosis was evaluated with quantitative real-time PCR, western blot and immunohistochemistry...
July 2016: Current Research in Translational Medicine
Masafumi Toyoshima, Keita Tsuji, Shogo Shigeta, Hideki Tokunaga, Kiyoshi Ito, Yoh Watanabe, Kosuke Yoshinaga, Takeo Otsuki, Hitoshi Niikura, Nobuo Yaegashi
Leptomeningeal metastasis (LM) is rarely observed in gynecologic cancers. As gadolinium-enhanced magnetic resonance imaging (Gd-MRI) is highly effective for diagnosing LM, the aim of this study is to describe the clinical behaviors and outcomes of LM patients who were diagnosed by Gd-MRI. After securing institutional review board approvals, we retrospectively reviewed patient records. Eight patients were found to have LM from gynecological malignancies. Primary tumors included three ovarian cancers, one tubal cancer, one peritoneal cancer, two endometrial cancers, and one cervical cancer...
September 30, 2016: Clinical Imaging
Arpit Bhargava, Dinesh K Mishra, Subodh K Jain, Rupesh K Srivastava, Nirmal K Lohiya, Pradyumna K Mishra
We aimed to identify an optimum nano-carrier system to deliver tumor antigen to dendritic cells (DCs) for efficient targeting of tumor reinitiating cells (TRICs) in gynecological malignancies. Different lipid based nano-carrier systems i.e. liposomes, ethosomes and solid lipid nanoparticles (SLNPs) were examined for their ability to activate DCs in allogeneic settings. Out of these three, the most optimized formulation was subjected for cationic and mannosylated surface modification and pulsed with DCs for specific targeting of tumor cells...
October 17, 2016: Molecular Immunology
Jingfu Liu, Na Wang, Yujuan Chen, Rong Lu, Xianren Ye
AIM: Venous thromboembolism (VTE) is a well-recognized complication in gynecological oncology patients, and has an impact on the overall outcome. The purpose of this study was to identify whether thrombelastography (TEG) predicts VTE in gynecological oncology patients. METHODS: This retrospective study included patients with gynecological oncology who were hospitalized at the Fujian Provincial Cancer Hospital from May 2014 to April 2016. Univariate and logistic regression multivariate analyses were performed to determine the clinical and laboratorial factors for VTE in gynecological oncology patients...
October 20, 2016: Journal of Obstetrics and Gynaecology Research
Nora K Horick, Adoma Manful, Jan Lowery, Susan Domchek, Patricia Moorman, Constance Griffin, Kala Visvanathan, Claudine Isaacs, Anita Y Kinney, Dianne M Finkelstein
PURPOSE: Registries provide a unique tool for tracking quality of life in rare cancer survivors, whose survivorship experience is less known than for common cancers. This paper reports on these outcomes in 321 patients enrolled in the Rare Cancer Genetics Registry diagnosed with rare gastrointestinal, genitourinary, gynecologic, sarcoma, head/neck, or hematologic cancers. METHODS: Four outcomes were assessed, reflecting registrants' self-reported physical and mental health, psychological distress, and loneliness...
October 19, 2016: Journal of Cancer Survivorship: Research and Practice
Qifang Long, Weipei Zhu, Jundong Zhou, Jinchang Wu, Weixian Lu, Cui Zheng, Dongmei Zhou, Ling Yu, Ru Yang
Ovarian cancer is one of the most lethal malignant gynecologic tumors with a high relapse rate worldwide. Cancer stem cells (CSC) have been identified in ovarian cancer and other malignant tumors as a small population of cells that are capable of self-renew and multi-differentiation. CD133 positive (CD133(+)) ovarian cancer stem cells have been reported to be more tumorigenic and more resistant to chemotherapeutic treatment. Thus, CD133 has emerged as one of the most promising therapeutic markers for ovarian cancer treatment...
October 18, 2016: Oncology Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"